Artificial virus-like particle could be harnessed to improve human health

Publicly released:
International
Venigalla B. Rao; Victor Padilla-Sanchez, Andrei Fokine, Jingen Zhu, and Qianglin Fang
Venigalla B. Rao; Victor Padilla-Sanchez, Andrei Fokine, Jingen Zhu, and Qianglin Fang

International researchers have built artificial virus-like particles capable of entering human cells to perform tasks such as gene editing. In a proof of concept study, the team used a type of virus that infects bacteria to design a method of building artificial viral vectors, or AVVs, which have large internal space for carrying material, and a large surface area for programming and delivering the biomolecules. The AVVs were able to successfully deliver the full-length dystrophin gene into human cells in the laboratory and perform various molecular operations to remodel the human genome. While more work needs to be done to assess its safety, the team says this tech could be used in the clinic to treat many human diseases and disorders down the track.

Media release

From: Springer Nature

Biotechnology: Artificial virus-like particles could be used to improve human health *IMAGE & VIDEOS*

A method of building artificial virus-like vectors capable of entering human cells to perform specific tasks, such as gene editing, is reported in Nature Communications this week. These large-capacity, customisable nanomaterials could be promising future candidates for gene therapy and personalised medicine.

Viruses are efficient biological machines capable of replicating and assembling progeny quickly. Natural human viruses, such as lentiviruses, have previously been engineered to deliver therapeutic DNA or RNA in animals, but these had limited delivery capabilities and several safety issues. Harnessing viral mechanisms by building artificial viral vectors programmed with therapeutic molecules could perform beneficial repairs to help restore human health.

Venigalla Rao and colleagues designed a method of building artificial viral vectors (AVV) using a type of virus that infects bacteria called bacteriophage T4. These AVVs have a large internal volume and a large external surface to program and deliver therapeutic biomolecules. In proof-of-concept experiments, the authors generated AVVs containing protein and nucleic acid cargo to demonstrate their use in genome engineering. The platform was able to successfully deliver the full-length dystrophin gene into human cells in the laboratory and perform various molecular operations to remodel the human genome. Furthermore, the AVVs can be produced inexpensively, at a high yield, and the nanomaterials were found to be stable for several months.

Although further work needs to be done to assess its safety, this method holds promise for future use in the clinic to treat many human diseases and rare disorders, the authors conclude.

Multimedia

Image 1
Image 1
Video 1
Video 2
Journal/
conference:
Nature Communications
Research:Paper
Organisation/s: The Catholic University of America, USA
Funder: This research was supported by NIAID/NIH grant AI111538 and in part by the National Science Foundation grant MCB-0923873 and NIAID/NIH grants AI081726 and AI175340 to V.B.R.
Media Contact/s
Contact details are only visible to registered journalists.